PMID- 1310252
OWN - NLM
STAT- MEDLINE
DCOM- 19920302
LR  - 20190515
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 65
IP  - 1
DP  - 1992 Jan
TI  - Three types of human lung tumour cell lines can be distinguished according to 
      surface expression of endogenous urokinase and their capacity to bind exogenous 
      urokinase.
PG  - 51-7
AB  - This study evaluates the cell surface expression of urokinase-type plasminogen 
      activator (u-PA) and the capacity to bind exogenous urokinase as possible 
      parameters for the distinction of various types of human lung tumours. Twelve 
      different tumour cell lines including four small cell carcinoma, two large cell 
      carcinoma, three squamous cell carcinoma, one adenocarcinoma and two mesothelioma 
      cell lines of lung origin were investigated. Surface expression of endogenous 
      u-PA was determined in a cellular radioimmunoassay (CRIA) using the u-PA-specific 
      monoclonal antibody 98/6. To estimate additional u-PA binding capacity, exogenous 
      two-chain, 54 kDa u-PA was employed in the CRIA. The influence of phorbol ester 
      (PMA) treatment on expression and binding of these molecules was studied. Three 
      different groups of lung tumour cell lines could be distinguished according to 
      their expression of u-PA and u-PA-binding ability: (i) non small cell lung 
      carcinoma (NSCLC) cell lines of squamous cell carcinoma/adenocarcinoma origin 
      expressed small amounts of u-PA and bound little u-PA. Large cell carcinoma cell 
      lines expressed high amounts of u-PA and bound large amounts of u-PA. In general, 
      expression of u-PA and u-PA binding was enhanced after PMA treatment. (ii) 
      Mesothelioma cell lines did not express u-PA, but were able to bind u-PA. (iii) 
      Small cell carcinoma (SCLC) lines were devoid of surface-expressed u-PA and could 
      not bind u-PA, both under untreated and PMA-treated conditions. It could thus be 
      demonstrated that these three groups of lung tumour cell lines differ in their 
      ability to express u-PA and to bind external u-PA. This may reflect the different 
      in vivo growth behaviour and origin of the respective tumour groups.
FAU - Schwartz-Albiez, R
AU  - Schwartz-Albiez R
AD  - Institute of Immunology and Genetics, German Cancer Research Center, Heidelberg.
FAU - Heidtmann, H H
AU  - Heidtmann HH
FAU - Wolf, D
AU  - Wolf D
FAU - Schirrmacher, V
AU  - Schirrmacher V
FAU - Moldenhauer, G
AU  - Moldenhauer G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Antibodies, Monoclonal)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - Adenocarcinoma/classification/enzymology
MH  - Antibodies, Monoclonal
MH  - Blotting, Western
MH  - Carcinoma, Non-Small-Cell Lung/classification/enzymology
MH  - Carcinoma, Small Cell/classification/enzymology
MH  - Carcinoma, Squamous Cell/classification/enzymology
MH  - Cell Line
MH  - Cell Membrane/enzymology
MH  - Humans
MH  - Immunochemistry
MH  - Kinetics
MH  - Lung Neoplasms/*classification/*enzymology
MH  - Mesothelioma/classification/enzymology
MH  - Protein Binding
MH  - Tetradecanoylphorbol Acetate/pharmacology
MH  - Urokinase-Type Plasminogen Activator/analysis/biosynthesis/*metabolism
PMC - PMC1977363
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1038/bjc.1992.10 [doi]
PST - ppublish
SO  - Br J Cancer. 1992 Jan;65(1):51-7. doi: 10.1038/bjc.1992.10.